{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T05:49:53Z","timestamp":1776232193900,"version":"3.50.1"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T00:00:00Z","timestamp":1763769600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,13]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>The present study aimed to evaluate the efficacy, safety, and retention rate of rituximab (RTX) in Japanese rheumatoid arthritis (RA) patients with a history of other iatrogenic immunodeficiency-associated lymphoproliferative disorders (OIIA-LPD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Between January 1, 2014, and July 31, 2024, 3\u2009392 RA patients were registered in our institutional database, and 74 of these had OIIA-LPD. Amongst patients who achieved remission after the onset of OIIA-LPD, those who subsequently received RTX were retrospectively identified. Clinical data, including the Disease Activity Score for 28 joints-C reactive protein (DAS28-CRP) value, Clinical Disease Activity Index (CDAI) score, adverse events, and RTX retention rate, were analyzed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Fourteen patients received RTX for RA after OIIA-LPD remission. The mean DAS28-CRP value at baseline and at month 6, 12, 24, and 36 was 3.91\u2009\u00b1\u20091.40, 3.03\u2009\u00b1\u20093.20, 2.45\u2009\u00b1\u20091.09, 2.22\u2009\u00b1\u20090.62, and 1.93\u2009\u00b1\u20090.78, respectively. The respective CDAI score was 15.2\u2009\u00b1\u20097.74, 4.91\u2009\u00b1\u20093.80, 6.19\u2009\u00b1\u20094.46, 5.08\u2009\u00b1\u20093.03, and 4.18\u2009\u00b1\u20093.28. Four infections were observed. The RTX retention rate at month 12, 24, and 36 was 85.1%, 76.6%, and 76.6%, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Even in real-world clinical practice, RTX demonstrated long-term efficacy in reducing disease activity in Japanese RA patients with a history of OIIA-LPD. RTX appears to be a viable treatment option for this patient population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/mr\/roaf114","type":"journal-article","created":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T12:56:10Z","timestamp":1763470570000},"page":"353-358","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and retention rate of rituximab in Japanese rheumatoid arthritis patients with a history of other iatrogenic immunodeficiency-associated lymphoproliferative disorders"],"prefix":"10.1093","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4535-8933","authenticated-orcid":false,"given":"Yoshiki","family":"Nagai","sequence":"first","affiliation":[{"name":"Department of Rheumatic Diseases, Tokyo Metropolitan Tama Medical Center , Tokyo ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-1225-4370","authenticated-orcid":false,"given":"Issei","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Rheumatic Diseases, Tokyo Metropolitan Tama Medical Center , Tokyo ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7814-443X","authenticated-orcid":false,"given":"Naoto","family":"Yokogawa","sequence":"additional","affiliation":[{"name":"Department of Rheumatic Diseases, Tokyo Metropolitan Tama Medical Center , Tokyo ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2860-4266","authenticated-orcid":false,"given":"Kota","family":"Shimada","sequence":"additional","affiliation":[{"name":"Department of Rheumatic Diseases, Tokyo Metropolitan Tama Medical Center , Tokyo ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,11,22]]},"reference":[{"key":"2026041500571560000_ref1","doi-asserted-by":"crossref","first-page":"R45","DOI":"10.1186\/ar2404","article-title":"A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis","volume":"10","author":"Smitten","year":"2008","journal-title":"Arthritis Res Ther"},{"key":"2026041500571560000_ref2","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1002\/1097-0215(20001101)88:3<497::AID-IJC27>3.0.CO;2-J","article-title":"Risk of malignancy among patients with rheumatic conditions","volume":"88","author":"Thomas","year":"2000","journal-title":"Int J Cancer"},{"key":"2026041500571560000_ref3","doi-asserted-by":"crossref","first-page":"642","DOI":"10.3109\/14397595.2016.1141740","article-title":"Risk for malignancy in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs compared to the general population: A nationwide cohort study in Japan","volume":"26","author":"Harigai","year":"2016","journal-title":"Mod Rheumatol"},{"key":"2026041500571560000_ref4","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1007\/s00296-010-1524-0","article-title":"Incidence of malignancy in Japanese patients with rheumatoid arthritis","volume":"31","author":"Yamada","year":"2011","journal-title":"Rheumatol Int"},{"key":"2026041500571560000_ref5","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.3899\/jrheum.150240","article-title":"Incidence and predictors of biological antirheumatic drug discontinuation attempts among patients with rheumatoid arthritis in remission: A CORRONA and NinJa collaborative cohort study","volume":"42","author":"Yoshida","year":"2015","journal-title":"J Rheumatol"},{"key":"2026041500571560000_ref6","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1080\/14397595.2020.1847775","article-title":"Treatment of rheumatoid arthritis after regression of lymphoproliferative disorders in patients treated with methotrexate: A retrospective, multi-center descriptive study","volume":"32","author":"Nakano","year":"2022","journal-title":"Mod Rheumatol"},{"key":"2026041500571560000_ref7","doi-asserted-by":"crossref","DOI":"10.1136\/ard-2022-223764","article-title":"EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update","volume":"83","author":"Hellmich","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"2026041500571560000_ref8","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1136\/ard-2023-224762","article-title":"EULAR recommendations for the management of systemic lupus erythematosus: 2023 update","volume":"83","author":"Fanouriakis","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"2026041500571560000_ref9","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1002\/acr.24596","article-title":"2021 American College of Rheumatology Guideline for the treatment of rheumatoid arthritis","volume":"73","author":"Fraenkel","year":"2021","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2026041500571560000_ref10","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1093\/mr\/roaf006","article-title":"2024 update of the Japan College of Rheumatology Clinical Practice Guidelines for the Management of Rheumatoid Arthritis: Secondary publication","volume":"35","author":"Harigai","year":"2025","journal-title":"Mod Rheumatol"},{"key":"2026041500571560000_ref11","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1136\/ard.2010.138461","article-title":"2010 rheumatoid arthritis classification criteria: An American College of Rheumatology\/European league against rheumatism collaborative initiative","volume":"69","author":"Aletaha","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"2026041500571560000_ref12","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/art.1780310302","article-title":"The American rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis","volume":"31","author":"Arnett","year":"1988","journal-title":"Arthritis Rheum"},{"key":"2026041500571560000_ref13","first-page":"1860","article-title":"Report of the committee on Hodgkin's disease staging classification","volume":"31","author":"Carbone","year":"1971","journal-title":"Cancer Res"},{"key":"2026041500571560000_ref14","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJM199309303291402","article-title":"A predictive model for aggressive non-Hodgkin's lymphoma","volume":"329","author":"International Non-Hodgkin's Lymphoma Prognostic Factors Project","year":"1993","journal-title":"N Engl J Med"},{"key":"2026041500571560000_ref15","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","volume":"82","author":"Smolen","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2026041500571560000_ref16","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1056\/NEJMoa032534","article-title":"Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis","volume":"350","author":"Edwards","year":"2004","journal-title":"N Engl J Med"},{"key":"2026041500571560000_ref17","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1002\/art.22025","article-title":"Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks","volume":"54","author":"Cohen","year":"2006","journal-title":"Arthritis Rheum"},{"key":"2026041500571560000_ref18","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1136\/annrheumdis-2011-200170","article-title":"Sustained inhibition of progressive joint damage with rituximab plus methotrexate in early active rheumatoid arthritis: 2-year results from the randomised controlled trial IMAGE","volume":"71","author":"Tak","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"2026041500571560000_ref19","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1136\/annrheumdis-2014-206015","article-title":"MRI assessment of suppression of structural damage in patients with rheumatoid arthritis receiving rituximab: Results from the randomised, placebo-controlled, double-blind RA-SCORE study","volume":"75","author":"Peterfy","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2026041500571560000_ref20","article-title":"Comparative effectiveness of rituximab, abatacept, and tocilizumab in adults with rheumatoid arthritis and inadequate response to TNF inhibitors: Prospective cohort study","volume":"364","author":"Gottenberg","year":"2019","journal-title":"BMJ."},{"key":"2026041500571560000_ref21","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1136\/annrheumdis-2021-220418","article-title":"Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 global rheumatology alliance physician registry","volume":"80","author":"Sparks","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2026041500571560000_ref22","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1007\/s00296-021-04969-2","article-title":"Protracted severe COVID-19 pneumonia following rituximab treatment: Caution needed","volume":"41","author":"Daoussis","year":"2021","journal-title":"Rheumatol Int"},{"key":"2026041500571560000_ref23","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1111\/1756-185X.14920","article-title":"Effectiveness and safety of rituximab in special types of rheumatoid arthritis","volume":"26","author":"Takanashi","year":"2023","journal-title":"Int J Rheum Dis"},{"key":"2026041500571560000_ref24","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1080\/14397595.2021.1879367","article-title":"Rheumatoid arthritis relapse in patients with other iatrogenic immunodeficiency-associated lymphoproliferative disorders and its treatment","volume":"31","author":"Nagafuchi","year":"2021","journal-title":"Mod Rheumatol"}],"container-title":["Modern Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mr\/advance-article-pdf\/doi\/10.1093\/mr\/roaf114\/65467650\/roaf114.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/36\/3\/353\/65467650\/roaf114.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/36\/3\/353\/65467650\/roaf114.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T04:57:24Z","timestamp":1776229044000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mr\/article\/36\/3\/353\/8340154"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,22]]},"references-count":24,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,11,22]]},"published-print":{"date-parts":[[2026,4,13]]}},"URL":"https:\/\/doi.org\/10.1093\/mr\/roaf114","relation":{},"ISSN":["1439-7595","1439-7609"],"issn-type":[{"value":"1439-7595","type":"print"},{"value":"1439-7609","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5]]},"published":{"date-parts":[[2025,11,22]]}}}